Clinical studies have demonstrated a significant benefit of the mTOR inhibitors temsirolimus (Torisel®; Wyeth Pharmaceuticals Inc., Philadelphia, PA, USA) and everolimus (Afinitor®; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA) in treating renal cell carcinoma (RCC) patients. Here, MTOR is linked to renal cell carcinoma.